Know Cancer

or
forgot password

Randomised-controlled Trial on the Immune Response to Single-port Access Versus Conventional Laparoscopic Colorectal Surgery


Phase 1/Phase 2
18 Years
N/A
Not Enrolling
Both
Colorectal Cancer, Inflammatory Bowel Disease, Benign Colorectal Neoplasm, Diverticular Disease

Thank you

Trial Information

Randomised-controlled Trial on the Immune Response to Single-port Access Versus Conventional Laparoscopic Colorectal Surgery


Inclusion Criteria:



- large bowel disorder requiring surgical resection

- body habitus suitable for single-port access surgery

Exclusion Criteria:

- patients not capable of informed consent and/or quality of life assessment

- planned open procedure for surgical reason

- multiple previous abdominal operations

- body-mass index > 40

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Outcome Measure:

IL-6

Outcome Description:

Immune response to tissue trauma (Interleukin-6)

Outcome Time Frame:

change from baseline at 2,6,24 and 72 hours from surgery

Safety Issue:

No

Authority:

United Kingdom: National Health Service

Study ID:

SUR-089

NCT ID:

NCT01626963

Start Date:

October 2012

Completion Date:

Related Keywords:

  • Colorectal Cancer
  • Inflammatory Bowel Disease
  • Benign Colorectal Neoplasm
  • Diverticular Disease
  • single-port access
  • laparoscopic surgery
  • surgical trauma
  • Neoplasms
  • Colorectal Neoplasms
  • Diverticulum
  • Inflammatory Bowel Diseases
  • Intestinal Diseases

Name

Location